nach oben

Erschienen in:

01.12.2014 | Original Article

Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy

verfasst von: B. Hofstetter, S. Gamsjaeger, F. Varga, H. Dobnig, J. J. Stepan, H. Petto, I. Pavo, K. Klaushofer, E. P. Paschalis

Erschienen in: Osteoporosis International | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

Summary

The results of the present study, involving analysis of biopsies from patients who received teriparatide for 2 years and were previously either treatment-naïve or on long-term alendronate therapy, suggest that prior alendronate use does not blunt the favorable effects of teriparatide on bone quality.

Introduction

Examine the effect of 2 years of teriparatide (TPTD) treatment on mineral and organic matrix properties of the newest formed bone in patients who were previously treatment-naïve (TN) or on long-term alendronate (ALN) therapy.

Methods

Raman and Fourier transform infrared microspectroscopic analyses were used to determine the mineral/matrix (M/M) ratio, the relative proteoglycan (PG) content, and the mineral maturity/crystallinity (MMC; determined by three methods: carbonate content, full width at half height of the v ₁PO₄ band [FWHH], and wavelength at maxima of the v ₁PO₄ band), as well as collagen maturity (ratio of pyridinoline/divalent cross-links), in paired iliac crest biopsies at trabecular, endosteal, and osteonal surfaces of newly formed bone in postmenopausal osteoporotic women who were previously either TN (n = 16) or receiving long-term ALN treatment (n = 24).

Results

Trabecular M/M ratio increased and matrix content decreased significantly in the ALN pretreated group. Collagen maturity decreased in both patient groups. Endosteal M/M ratio increased significantly in the TN group. Trabecular M/M ratio was higher at endpoint in the ALN pretreated group than in the TN group. Overall, no changes from baseline were observed in PG content, except that PG content was higher in the ALN pretreated group than in the TN group at endosteal surfaces at endpoint. The ability of TPTD treatment to reduce MMC in both patient groups and at the different bone surfaces depended on the measurement tool (relative carbonate content or wavelength at maxima of the v ₁PO₄ band). None of the changes in MMC were different between the two patient groups.

Conclusions

The results suggest some favorable impact of TPTD on bone mineral and organic matrix properties of in situ forming bone in terms of increased initial mineralization and decreased MMC and collagen maturity. Moreover, prior long-term ALN administration may have only limited influence on these properties in bone newly formed after 2 years of TPTD treatment.

Nur mit Berechtigung zugänglich

Riggs BL, Parfitt AM (2005) Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 20:177–184PubMedCrossRef

Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491PubMedCrossRef

Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M (2010) Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267–2294PubMedCrossRef

Compston J (2005) Recombinant parathyroid hormone in the management of osteoporosis. Calcif Tissue Int 77:65–71PubMedCrossRef

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRef

Pleiner-Duxneuner J, Zwettler E, Paschalis E, Roschger P, Nell-Duxneuner V, Klaushofer K (2009) Treatment of osteoporosis with parathyroid hormone and teriparatide. Calcif Tissue Int 84:159–170PubMedCrossRef

Paschalis EP, Glass EV, Donley DW, Eriksen EF (2005) Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: New results from the fracture prevention trial. J Clin Endocrinol Metab 90:4644–4649PubMedCrossRef

Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK, McCloskey EV, Beneton MN, Gertz BJ, Sciberras DG, Holland SD, Orgee J, Coombes GM, Rogers SR, Porras AG (1997) Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 12:1700–1707PubMedCrossRef

Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745–751PubMedCrossRef

10.

Ma Y, Zeng Q, Chiang A, Burr D, Li J, Dobnig H, Fahrleitner-Pammer A, Michalská D, Marin F, Pavo I, Stepan J (2014) Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment. Bone.

11.

Stepan JJ, Burr DB, Li J, Ma YL, Petto H, Sipos A, Dobnig H, Fahrleitner-Pammer A, Michalska D, Pavo I (2010) Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis. Osteoporos Int 21:2027–2036PubMedCrossRef

12.

Boonen S, Marin F, Obermayer-Pietsch B, Simoes ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey EV (2008) Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93:852–860PubMedCrossRef

13.

Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP (2008) Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 93:3785–3793PubMedCrossRef

14.

Fratzl P, Gupta H, Paschalis E, Roschger P (2004) Structure and mechanical quality of the collagen–mineral nano-composite in bone. J Mater Chem 14:2115–2123CrossRef

15.

Gamsjaeger S, Buchinger B, Zoehrer R, Phipps R, Klaushofer K, Paschalis EP (2011) Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate. Bone 49:1160–1165PubMedCrossRef

16.

Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH (2006) Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 38:617–627PubMedCrossRef

17.

Idris AI, Rojas J, Greig IR, Van’t Hof RJ, Ralston SH (2008) Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 82:191–201PubMedCrossRef

18.

Nebe B, Finke B, Luthen F, Bergemann C, Schroder K, Rychly J, Liefeith K, Ohl A (2007) Improved initial osteoblast functions on amino-functionalized titanium surfaces. Biomol Eng 24:447–454PubMedCrossRef

19.

Roelofs AJ, Coxon FP, Ebetino FH, Lundy MW, Henneman ZJ, Nancollas GH, Sun S, Blazewska KM, Bala JL, Kashemirov BA, Khalid AB, McKenna CE, Rogers MJ (2010) Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 25:606–616PubMedCentralPubMedCrossRef

20.

Smith IO, Baumann MJ, Obadia L, Bouler JM (2004) Surface potential and osteoblast attraction to calcium phosphate compounds is affected by selected alkaline hydrolysis processing. J Mater Sci Mater Med 15:841–846PubMedCrossRef

21.

Gamsjaeger S, Buchinger B, Zwettler E, Recker R, Black D, Gasser JA, Eriksen EF, Klaushofer K, Paschalis EP (2010) Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly zoledronic acid. J Bone Miner Res 26:12–18CrossRef

22.

Roelofs AJ, Stewart CA, Sun S, Blazewska KM, Kashemirov BA, McKenna CE, Russell RG, Rogers MJ, Lundy MW, Ebetino FH, Coxon FP (2012) Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo. J Bone Miner Res 27:835–847PubMedCrossRef

23.

Dobnig H, Stepan JJ, Burr DB, Li J, Michalska D, Sipos A, Petto H, Fahrleitner-Pammer A, Pavo I (2009) Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate. J Bone Miner Res 24:1998–2006PubMedCrossRef

24.

Gamsjaeger S, Masic A, Roschger P, Kazanci M, Dunlop JW, Klaushofer K, Paschalis EP, Fratzl P (2010) Cortical bone composition and orientation as a function of animal and tissue age in mice by Raman spectroscopy. Bone 47:392–399PubMedCrossRef

25.

Kazanci M, Wagner HD, Manjubala NI, Gupta HS, Paschalis E, Roschger P, Fratzl P (2007) Raman imaging of two orthogonal planes within cortical bone. Bone 41:456–461PubMedCrossRef

26.

Ellis R, Green E, Winlove C (2009) Structural analysis of glycosaminoglycans and proteoglycans by means of raman microspectrometry. Connect Tissue Res 50:29–36PubMedCrossRef

27.

Kazanci M, Fratzl P, Klaushofer K, Paschalis EP (2006) Complementary information on in vitro conversion of amorphous (precursor) calcium phosphate to hydroxyapatite from Raman microspectroscopy and wide-angle X-ray scattering. Calcif Tissue Int 79:354–359PubMedCrossRef

28.

Dong A, Huang P, Caughey WS (1990) Protein secondary structures in water from second-derivative amide I infrared spectra. Biochemistry 29:3303–3308PubMedCrossRef

29.

Paschalis EP, Verdelis K, Doty SB, Boskey AL, Mendelsohn R, Yamauchi M (2001) Spectroscopic characterization of collagen cross-links in bone. J Bone Miner Res 16:1821–1828PubMedCrossRef

30.

Paschalis EP, Tatakis DN, Robins S, Fratzl P, Manjubala I, Zoehrer R, Gamsjaeger S, Buchinger B, Roschger A, Phipps R, Boskey AL, Dall’ara E, Varga P, Zysset P, Klaushofer K, Roschger P (2011) Lathyrism-induced alterations in collagen cross-links influence the mechanical properties of bone material without affecting the mineral. Bone 49:1232–1241PubMedCentralPubMedCrossRef

31.

Bala Y, Depalle B, Farlay D, Douillard T, Meille S, Follet H, Chapurlat R, Chevalier J, Boivin G (2012) Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization. J Bone Miner Res 27:825–834PubMedCrossRef

32.

Bala Y, Farlay D, Chapurlat RD, Boivin G (2011) Modifications of bone material properties in postmenopausal osteoporotic women long-term treated with alendronate. Eur J Endocrinol/Eur Fed Endocr Soc 165:647–655CrossRef

33.

Einhorn TA (1996) The bone organ system: Form and function. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis. Academic, New York

34.

Morris MD, Mandair GS (2011) Raman assessment of bone quality. Clin Orthop Relat Res 469:2160–2169PubMedCentralPubMedCrossRef

35.

Paschalis EP, Mendelsohn R, Boskey AL (2011) Infrared assessment of bone quality: a review. Clin Orthop Relat Res 469:2170–2178PubMedCentralPubMedCrossRef

36.

Spevak L, Flach CR, Hunter T, Mendelsohn R, Boskey A (2013) Fourier transform infrared spectroscopic imaging parameters describing acid phosphate substitution in biologic hydroxyapatite. Calcif Tissue Int 92:418–428PubMedCentralPubMedCrossRef

37.

Donnelly E, Chen DX, Boskey AL, Baker SP, van der Meulen MC (2010) Contribution of mineral to bone structural behavior and tissue mechanical properties. Calcif Tissue Int 87:450–460PubMedCentralPubMedCrossRef

38.

Helvering LM, Liu R, Kulkarni NH, Wei T, Chen P, Huang S, Lawrence F, Halladay DL, Miles RR, Ambrose EM, Sato M, Ma YL, Frolik CA, Dow ER, Bryant HU, Onyia JE (2005) Expression profiling of rat femur revealed suppression of bone formation genes by treatment with alendronate and estrogen but not raloxifene. Mol Pharmacol 68:1225–1238PubMedCrossRef

39.

Fuchs RK, Faillace ME, Allen MR, Phipps RJ, Miller LM, Burr DB (2011) Bisphosphonates do not alter the rate of secondary mineralization. Bone 49:701–705PubMedCrossRef

40.

Aparicio S, Doty SB, Camacho NP, Paschalis EP, Spevak L, Mendelsohn R, Boskey AL (2002) Optimal methods for processing mineralized tissues for Fourier transform infrared microspectroscopy. Calcif Tissue Int 70:422–429PubMedCrossRef

41.

Paschalis EP, DiCarlo E, Betts F, Sherman P, Mendelsohn R, Boskey AL (1996) FTIR microspectroscopic analysis of human osteonal bone. Calcif Tissue Int 59:480–487PubMedCrossRef

42.

Henneman ZJ, Nancollas GH, Ebetino FH, Russell RG, Phipps RJ (2008) Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro. J Biomed Mater Res A 85:993–1000PubMedCentralPubMedCrossRef

43.

Blank RD, Baldini TH, Kaufman M, Bailey S, Gupta R, Yershov Y, Boskey AL, Coppersmith SN, Demant P, Paschalis EP (2003) Spectroscopically determined collagen Pyr/deH-DHLNL cross-link ratio and crystallinity indices differ markedly in recombinant congenic mice with divergent calculated bone tissue strength. Connect Tissue Res 44:134–142PubMedCrossRef

44.

Malluche HH, Porter DS, Mawad H, Monier-Faugere MC, Pienkowski D (2013) Low-energy fractures without low T-scores characteristic of osteoporosis: a possible bone matrix disorder. J Bone Joint Surg Am 95:e1391–e1396PubMedCrossRef

45.

Misof BM, Gamsjaeger S, Cohen A, Hofstetter B, Roschger P, Stein E, Nickolas TL, Rogers HF, Dempster D, Zhou H, Recker R, Lappe J, McMahon D, Paschalis EP, Fratzl P, Shane E, Klaushofer K (2012) Bone material properties in premenopausal women with idiopathic osteoporosis. J Bone Miner Res 27:2551–2561PubMedCentralPubMedCrossRef

46.

Paschalis EP, Shane E, Lyritis G, Skarantavos G, Mendelsohn R, Boskey AL (2004) Bone fragility and collagen cross-links. J Bone Miner Res 19:2000–2004PubMedCentralPubMedCrossRef

47.

Boskey AL, DiCarlo E, Paschalis E, West P, Mendelsohn R (2005) Comparison of mineral quality and quantity in iliac crest biopsies from high- and low-turnover osteoporosis: an FT-IR microspectroscopic investigation. Osteoporos Int 16:2031–2038PubMedCentralPubMedCrossRef

48.

Boskey AL, Spevak L, Doty SB, Rosenberg L (1997) Effects of bone CS-proteoglycans, DS-decorin, and DS-biglycan on hydroxyapatite formation in a gelatin gel. Calcif Tissue Int 61:298–305PubMedCrossRef

49.

Mochida Y, Parisuthiman D, Pornprasertsuk-Damrongsri S, Atsawasuwan P, Sricholpech M, Boskey AL, Yamauchi M (2009) Decorin modulates collagen matrix assembly and mineralization. Matrix Biol 28:44–52PubMedCentralPubMedCrossRef

50.

Nielsen KL, Allen MR, Bloomfield SA, Andersen TL, Chen XD, Poulsen HS, Young MF, Heegaard AM (2003) Biglycan deficiency interferes with ovariectomy-induced bone loss. J Bone Miner Res 18:2152–2158PubMedCrossRef

51.

Gualeni B, de Vernejoul MC, Marty-Morieux C, De Leonardis F, Franchi M, Monti L, Forlino A, Houillier P, Rossi A, Geoffroy V (2013) Alteration of proteoglycan sulfation affects bone growth and remodeling. Bone 54:83–91PubMedCentralPubMedCrossRef

52.

Smith AJ, Singhrao SK, Newman GR, Waddington RJ, Embery G (1997) A biochemical and immuno-electron microscopical analysis of chondroitin sulphate-rich proteoglycans in human alveolar bone. Histochem J 29:1–9PubMedCrossRef

53.

Paschalis EP, Betts F, DiCarlo E, Mendelsohn R, Boskey AL (1997) FTIR microspectroscopic analysis of human iliac crest biopsies from untreated osteoporotic bone. Calcif Tissue Int 61:487–492PubMedCrossRef

54.

Akkus O, Adar F, Schaffler MB (2004) Age-related changes in physicochemical properties of mineral crystals are related to impaired mechanical function of cortical bone. Bone 34:443–453PubMedCrossRef

55.

Gamsjaeger S, Hofstetter B, Zwettler E, Recker R, Gasser JA, Eriksen EF, Klaushofer K, Paschalis EP (2012) Effects of 3 years treatment with once-yearly zoledronic acid on the kinetics of bone matrix maturation in osteoporotic patients. Osteoporosis International in press

56.

Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159PubMedCrossRef

57.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods 25:402–408PubMedCrossRef

Titel: Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy
verfasst von: B. Hofstetter
S. Gamsjaeger
F. Varga
H. Dobnig
J. J. Stepan
H. Petto
I. Pavo
K. Klaushofer
E. P. Paschalis
Publikationsdatum: 01.12.2014
Verlag: Springer London
Erschienen in: Osteoporosis International / Ausgabe 12/2014
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-014-2814-2

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy

Abstract

Summary

Introduction

Methods

Results

Conclusions

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Brustkrebs in der Vorgeschichte macht Gelenkersatz komplikationsträchtiger

Zwei neue Alternativen zu TNF-Inhibitoren bei axSpA

Update Orthopädie und Unfallchirurgie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Summary

Introduction

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2014

Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption–formation cycles?

Erratum to: Prevalence of renal impairment among osteoporotic women in the USA, NHANES 2005–2008: is treatment with bisphosphonates an option?

Associations of polymorphisms in the SOST gene and bone mineral density in postmenopausal Chinese Women

A trabecular plate-like phenotype is overrepresented in Chinese-American versus Caucasian women

Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study

Incidence and risk factors for osteoporotic vertebral fracture in low-income community-dwelling elderly: a population-based prospective cohort study in Brazil. The São Paulo Ageing & Health (SPAH) Study

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Brustkrebs in der Vorgeschichte macht Gelenkersatz komplikationsträchtiger

Zwei neue Alternativen zu TNF-Inhibitoren bei axSpA

Update Orthopädie und Unfallchirurgie